• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

[高钾血症——当前的治疗策略]

[Hyperkalemia - current therapuetic strategies].

作者信息

Głogowski Tomasz, Wojtaszek Ewa

机构信息

Katedra i Klinika Nefrologii, Dializoterapii i Chorób Wewnętrznych WUM, Warszawa, Polska,

Katedra i Klinika Nefrologii, Dializoterapii i Chorób Wewnętrznych WUM, Warszawa, Polska.

出版信息

Wiad Lek. 2016;69(5):745-748.

PMID:28033600
Abstract

Hyperkalemia is a medical emergency that requires immediate therapy, followed by interventions aimed at preventing its recurrence. Hyperkalemia occurs especially frequently in patients with chronic kidney disease (CKD), in part because of impaired kidney function and in part due to coexisting comorbidities such as diabetes or heart failure and the medications used to treat them, first of all the inhibitors of renin-angiotensin-aldosterone system (RAASi). Both acute and chronic management of hyperkalemia are equally important, though, with currently available therapeutic possibilities, the effective restoration of potassium homeostasis are in fact limited to the correction of its triggers. The emergence of new medications (patiromer and ZS-9) could lead to a therapeutic paradigm shift from intermittent treatment of incidentally discovered hyperkalemia toward preventive measures preventing fluctuations in serum potassium levels and enabling the continuation of beneficial, but hyperkalemia inducing agents.

摘要

高钾血症是一种需要立即治疗的医疗急症,随后需采取措施预防其复发。高钾血症在慢性肾脏病(CKD)患者中尤为常见,部分原因是肾功能受损,部分原因是并存的合并症,如糖尿病或心力衰竭以及用于治疗这些疾病的药物,首先是肾素 - 血管紧张素 - 醛固酮系统抑制剂(RAASi)。不过,高钾血症的急性和慢性管理同样重要,尽管有目前可用的治疗方法,但实际上有效恢复钾稳态仅限于纠正其触发因素。新药物(帕替罗姆和ZS - 9)的出现可能导致治疗模式从偶然发现的高钾血症的间歇性治疗转向预防血清钾水平波动并允许继续使用有益但会诱发高钾血症的药物的预防措施。

相似文献

1
[Hyperkalemia - current therapuetic strategies].[高钾血症——当前的治疗策略]
Wiad Lek. 2016;69(5):745-748.
2
New drugs to prevent and treat hyperkalemia.预防和治疗高钾血症的新药。
Curr Opin Nephrol Hypertens. 2016 Nov;25(6):524-528. doi: 10.1097/MNH.0000000000000272.
3
Patiromer: a clinical review.帕替罗姆:一项临床综述。
Curr Med Res Opin. 2016;32(1):155-64. doi: 10.1185/03007995.2015.1106935. Epub 2015 Nov 19.
4
[Hyperkalemia treatment in chronic kidney disease patients: overview on new K binders and possible therapeutic approaches].[慢性肾脏病患者高钾血症的治疗:新型钾结合剂及可能的治疗方法概述]
G Ital Nefrol. 2018 Sep;35(5).
5
[Hyperkalemia as a limiting factor in the use of drugs that block the Renin Angiotensin Aldosterone System (RAAS)].高钾血症作为限制使用阻断肾素-血管紧张素-醛固酮系统(RAAS)药物的一个因素
G Ital Nefrol. 2018 May;35(3).
6
New Therapeutic Approaches for the Treatment of Hyperkalemia in Patients Treated with Renin-Angiotensin-Aldosterone System Inhibitors.治疗肾素-血管紧张素-醛固酮系统抑制剂治疗患者高钾血症的新治疗方法。
Cardiovasc Drugs Ther. 2018 Feb;32(1):99-119. doi: 10.1007/s10557-017-6767-5.
7
Potassium Binders for Hyperkalemia in Chronic Kidney Disease-Diet, Renin-Angiotensin-Aldosterone System Inhibitor Therapy, and Hemodialysis.慢性肾脏病高钾血症的钾结合剂:饮食、肾素-血管紧张素-醛固酮系统抑制剂治疗和血液透析。
Mayo Clin Proc. 2020 Feb;95(2):339-354. doi: 10.1016/j.mayocp.2019.05.019. Epub 2019 Oct 23.
8
Effect of Patiromer on Hyperkalemia Recurrence in Older Chronic Kidney Disease Patients Taking RAAS Inhibitors.帕替洛默尔对服用 RAAS 抑制剂的老年慢性肾脏病患者高钾血症复发的影响。
Am J Med. 2018 May;131(5):555-564.e3. doi: 10.1016/j.amjmed.2017.11.011. Epub 2017 Nov 26.
9
Advances in treatment of hyperkalemia in chronic kidney disease.慢性肾脏病高钾血症治疗进展
Expert Opin Pharmacother. 2015;16(14):2205-15. doi: 10.1517/14656566.2015.1083977. Epub 2015 Sep 2.
10
The tolerability and safety profile of patiromer: a novel polymer-based potassium binder for the treatment of hyperkalemia.帕替络尔的耐受性和安全性特征:一种新型聚合物钾结合剂,用于治疗高钾血症。
Expert Opin Drug Saf. 2018 May;17(5):525-535. doi: 10.1080/14740338.2018.1462335. Epub 2018 Apr 22.